ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Anti-VEGF therapy for symptomatic exudative retinal arterial macroaneurysms: functional and anatomic outcomes with OCTA findings.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo evaluate the clinical outcomes of symptomatic exudative retinal arterial macroaneurysms (RAMs) following anti-vascular endothelial growth factor (anti-VEGF) therapy.
methodsThis retrospective study included treatment-naïve patients with exudative RAM who received anti-VEGF injections and were followed for ≥ 6 months. Clinical data and multimodal imaging findings, including optical coherence tomography angiography (OCTA), were analyzed.
resultsThirty-seven eyes (37 patients) were included. The mean number of anti-VEGF injections was 2.4 ± 1.5 over a mean follow-up of 10.1 ± 4.3 months. BCVA, measured as the logarithm of the minimum angle of resolution (Snellen equivalent), improved significantly from 0.97 ± 0.42 (20/187) at baseline to 0.62 ± 0.36 (20/84) at the final visit (P < 0.001). CST decreased from 548.3 ± 180.4 μm to 285.8 ± 76.9 μm (P < 0.001). Baseline OCTA identified two morphologic types of RAMs: type 1 (distended, 68.3%) and type 2 (meshed, 31.7%). Both types exhibited reduced flow signals and shrank after treatment. B-scan OCTA revealed the absence of flow signals in RAM lesions in 22 eyes (59.5%) and complete resolution of macular edema in 32 eyes (86.5%). Subgroup analysis showed that type 1 RAMs required more anti-VEGF injections than type 2 RAMs (2.79 ± 1.59 vs. 1.69 ± 1.11, P = 0.03). Baseline BCVA was an independent predictor of final BCVA (P < 0.001).
conclusionIntravitreal anti-VEGF therapy for exudative RAMs is associated with functional and anatomical improvement. OCTA-based morphologic classification may predict therapeutic response, with type 1 RAMs requiring a higher treatment burden.
Indexed as
Identifiers
41874678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.